NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

OJ,

Fortunately the one who fronted $3m would not wait until the publication of the results on peer-reviewed journal trust what he/she sees.

It's not promotional. If it were promotional, the research on combination therapy would have been presented too.

One thing for sure what we have seem is just the tip of an iceberg. If they tested whether DCVax-L can be loaded with antigens from various solid tumors. Would they test DCVax-L alone and its combinations on animal models? Absolutely! Would they do the same ex vivo? Absolutely!
Tens of patients with different types tumors received the DCVax-L treatment through compassionate program. It could be DCVax-L alone or its combinations. If a rGBM patient who were supposed to go to hospice is still alive and there is no recurrence after receiving DCVax-L. What about patients with other tumors?

Now you are telling us that we should not be excited. We should be more excited than ever! Peer-reviewed publication will come sooner or later. It is just a matter of time and a formality.